Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 537 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06002789RecruitingPhase 2
PD-1 immunotherapy with or without chemo before surgery for colorectal cancer
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
Guangzhou, GuangdongAges 18–80 - NCT06008054RecruitingPhase 2
New drug combo for advanced gastrointestinal cancers
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
Beijing, Beijing MunicipalityAges 18–75 - NCT06041477RecruitingPhase 3
Combining treatments for liver cancer before surgery
This study tests whether giving targeted therapy and immunotherapy at the same time or one after the other is better for shrinking liver tumors that can't be removed right now but might be removable after treatment.
Guangzhou, GuangdongAges 18–75 - NCT06168851RecruitingPhase 2
Anti-CD38 antibody for children with chronic ITP
This trial tests a new drug called anti-CD38 antibody for children and teens with chronic immune thrombocytopenia (ITP) whose platelet counts remain low despite other treatments. It may help increase platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 6–17 - NCT06205849RecruitingPhase 1
Testing a new drug and procedure for advanced pancreatic cancer
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
La Jolla, CaliforniaAges 18 years+ - NCT06259552RecruitingPhase 1
Study of SPX-303 for advanced solid tumors
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT06259721RecruitingPhase 2
New drug combo for advanced nasopharyngeal cancer after platinum failure
This trial tests a combination of three drugs—an anti-PD1 immunotherapy, nimotuzumab (targets EGFR), and capecitabine (chemotherapy)—for people whose nasopharyngeal cancer has returned or spread and no longer responds to platinum-based chemotherapy. The goal is to see if this combination can help when standard treatment stops working.
Nanchang, JiangxiAges 18–70 - NCT05999084Enrolling by invitation
Georgia Memory Net Anti-Amyloid Antibody Study
This study tests antibody treatments that target amyloid plaques in the brain for people with mild memory or thinking problems. It may help determine if you are a candidate for these new drugs and monitors your safety through regular scans and checkups.
Albany, GeorgiaAges 50–90 - NCT06468280RecruitingPhase 2
Immunotherapy and chemo with surgery for limited-spread stomach cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
Shanghai, Shanghai CityAges 18–79 - NCT06515106Recruiting
Living with LGI1 encephalitis: a study on long-term symptoms
This study looks at symptoms, biomarkers, and mechanisms of the chronic phase of LGI1 antibody-mediated encephalitis. It aims to understand what happens after the acute stage and how to better manage long-term effects.
Barcelona, CataloniaAges Any age - NCT06542588RecruitingPhase 2
Short radiation plus chemo and immunotherapy for rectal cancer
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT07689630RecruitingPhase 3
Antibody to prevent GVHD in half-matched stem cell transplant
This study is testing whether giving a special antibody (anti-CD25) before a half-matched stem cell transplant can prevent a common side effect called graft-versus-host disease (GVHD), where donor cells attack your body. It is for people with blood cancers who are getting this type of transplant.
Wuhan, HubeiAges 18–75 - NCT06650826Recruiting
Antibodies and blood clots in young adults
This study looks for certain antibodies in the blood of people aged 18 to 60 who have had a blood clot without a clear cause, or soon after an infection or vaccine, or who have had clots return despite treatment. It aims to understand why these clots happen.
BerlinAges 18–60 - NCT05204147RecruitingPhase 1
Radioactive antibody for CEA-making advanced cancers
This early-phase trial tests a radioactive antibody (Ac225-DOTA-M5A) that targets CEA, a protein found on many cancer cells. It's for people with advanced or metastatic cancers that produce CEA and who have no good standard treatment options left.
Duarte, CaliforniaAges 18 years+ - NCT06741995Recruiting
Testing antibodies to predict heart muscle disease progression
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
Wuhan, HubeiAges 18–75 - NCT06791512RecruitingPhase 3
Chemo Plus Targeted Therapy With or Without Immunotherapy for Colorectal Cancer
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
Guangzhou, GuangdongAges 18–80 - NCT06832228Recruiting
Study of Pomalidomide with Rituximab and Immunotherapy for DLBCL
This trial tests a combination of three drugs (pomalidomide, rituximab, and an immunotherapy called anti-PD-1) for people with diffuse large B-cell lymphoma that has not responded or has come back after two prior treatments. The goal is to see if this combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18–80 - NCT06846385RecruitingPhase 2/Phase 3
Testing a new shot for severe seasonal hay fever
This study tests a new injection called MG-K10 for people with moderate-to-severe seasonal hay fever that isn't well controlled by standard treatments like nasal sprays or antihistamines. The goal is to see if it can reduce your allergy symptoms over the pollen season.
Beijing, Beijing MunicipalityAges 18–75 - NCT06877416Recruiting
Optimizing sequential ADC therapy for HER2-low breast cancer
This trial is for people with HER2-low breast cancer who have already received two or more antibody-drug conjugates (ADCs) in a row. Researchers want to find the best order to use these targeted therapies to get the most benefit.
Guangzhou, GuangdongAges Any age - NCT06892223RecruitingPhase 2
Anti-NKG2A antibody for leukemia or MDS after half-matched transplant
This trial tests a drug that targets NKG2A, a protein that may help prevent cancer cells from hiding from the immune system. It is for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related conditions who have already received a half-matched stem cell transplant (haploidentical transplant) with a specific anti-rejection drug plan.
Genova, GENOVAAges 18–99 - NCT06921239Recruiting
HLA antibodies in lupus patients
This study looks for certain immune markers (HLA antibodies) in stored blood samples from people with lupus. It may help doctors understand how the immune system behaves in lupus.
AmiensAges 18 years+ - NCT06936046RecruitingPhase 2
Enhanced treatment for newly diagnosed GBM with partial resection or early progression
This trial tests a stronger combination of treatments given after surgery for people with glioblastoma (GBM) that was only partially removed or that starts growing again quickly. It aims to see if this approach can help control the tumor better. You may be eligible if you are newly diagnosed, over 18, have good organ function, and do not have other serious health issues.
HangzhouAges 18 years+ - NCT06967480Recruiting
Early ravulizumab for recent-onset generalized myasthenia gravis
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
BergamoAges 18 years+ - NCT07133113Recruiting
Effects of treatments in autoimmune encephalitis
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
BronAges Any age
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 537 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.